Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indi-blade bladder-sparing immunotherapy followed by chemoradiotherapy study
NL-OMON60120Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in transitional cell carcinoma of the bladder (TCC) and bladder cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Bladder-intact event-free survival. Started Jan 2022; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
transitional cell carcinoma of the bladder (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON60120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60120.